Scholar Rock announces FDA approval of IsembYld™ (apitegromab-mstn), the first and only muscle-targeted treatment for children and adults with spinal muscular atrophy (SMA)
Scholar Rock Holding Corporation - IsembYld U.S. commercial launch underway; product available to ship in coming days
SRRK•
